Praxis Precision Medicine Q2 2024 GAAP EPS $(1.74) Beats $(2.31) Estimate, Sales $357.000K Miss $870.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
Praxis Precision Medicine (NASDAQ:PRAX) reported Q2 2024 GAAP EPS of $(1.74), beating the estimate of $(2.31). However, sales of $357,000 missed the $870,000 estimate and decreased by 54.29% from the same period last year.
August 13, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Praxis Precision Medicine reported better-than-expected EPS but significantly missed sales estimates and showed a substantial year-over-year decline in sales.
While the EPS beat is positive, the significant miss on sales and the large year-over-year decline in revenue are likely to weigh heavily on investor sentiment, leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100